[G23-25] Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45
Last updated 01.12.2023
Project no.:
G23-25
Commission:
Commission awarded on 26.09.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
The current version 1.1 of the addendum replaces version 1.0 published on 2023-11-17.
DOI:
https://dx.doi.org/10.60584/G23-25_V1.1
| Project no. | Title | Status |
|---|---|---|
| A23-45 | Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-11-16 A G-BA decision was published.